Profile data is unavailable for this security.
About the company
Fagron NV, formerly Arseus NV, is a Belgium-based company that is active in the healthcare sector. It operates as a research and development (R&D) scientific pharmaceutical compounding supplier and operates through four segments: The Fagron Specialty Pharma Services segment comprises personalized medication that is produced in the Company's compounding facilities; the Fagron Trademarks segment encompasses concepts and formulations developed by the Company's research and development (R&D) team; Fagron Essentials comprises pharmaceutical raw materials, equipment and supplies for pharmacies, and the HL Technology segment includes the development and production of precision components and orthopedic tools for dental and medical professionals.
- Revenue in EUR (TTM)534.70m
- Net income in EUR55.20m
- Incorporated2007
- Employees2.73k
- LocationFagron NVVenecoweg 20ANAZARETH 9810BelgiumBEL
- Phone+32 80012880
- Fax+32 92162491
- Websitehttps://fagron.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Puretech Health PLC | 8.66m | 371.76m | 910.22m | 300.00 | 2.43 | 1.54 | 2.77 | 105.14 | 1.18 | 1.18 | 0.027 | 1.86 | 0.0142 | -- | 5.93 | 25,925.79 | 52.94 | 4.21 | 66.31 | 6.05 | -- | -- | 3,732.69 | 163.04 | -- | -- | 0.057 | 0.00 | -52.73 | 34.57 | 1,064.73 | -- | 97.24 | -- |
| Recipharm AB (publ) | 790.20m | 3.20m | 949.22m | 7.29k | 470.76 | 1.66 | 11.12 | 1.20 | 0.2638 | 0.2638 | 102.84 | 74.81 | 0.441 | 2.50 | 4.66 | 1,199,156.00 | 0.1793 | 1.52 | 0.2025 | 1.75 | 47.00 | 48.07 | 0.4066 | 2.77 | 1.50 | 2.22 | 0.7082 | 34.23 | 17.00 | 23.75 | 115.18 | 16.45 | 11.35 | -- |
| FAES Farma SA | 378.09m | 68.43m | 1.01bn | 1.44k | 14.46 | -- | 12.28 | 2.68 | 0.2459 | 0.2459 | 1.35 | -- | -- | -- | -- | 262,564.60 | -- | 11.78 | -- | 13.83 | 63.08 | 64.38 | 18.12 | 16.14 | -- | 74.06 | -- | -- | 10.20 | 13.26 | 23.98 | 20.35 | 38.84 | -- |
| Dottikon ES Holding AG | 164.40m | 31.19m | 1.02bn | 606.00 | 32.10 | 2.64 | 20.76 | 6.19 | 26.48 | 26.48 | 139.56 | 321.52 | 0.3668 | 0.4756 | 4.58 | 288,399.30 | 6.96 | 5.49 | 7.87 | 6.12 | 80.17 | 82.60 | 18.97 | 14.81 | 1.58 | -- | 0.00 | 0.00 | 18.32 | 12.61 | 103.97 | 90.29 | 34.84 | -- |
| Hansa Biopharma AB | 319.60k | -36.54m | 1.05bn | 78.00 | -- | 23.07 | -- | 3,281.85 | -9.52 | -9.52 | 0.0833 | 11.84 | 0.0046 | -- | 0.3484 | 45,027.03 | -52.99 | -38.19 | -57.02 | -41.55 | 73.35 | 85.18 | -11,431.57 | -4,954.36 | -- | -164.28 | 0.0193 | -- | 0.1787 | 15.76 | -45.18 | -- | 23.28 | -- |
| Clinigen Group PLC | 547.29m | 15.69m | 1.14bn | 130.00 | 74.21 | 2.32 | 15.72 | 2.08 | 0.1038 | 0.1038 | 3.68 | 3.32 | 0.5101 | 7.23 | 4.25 | 3,782,308.00 | 1.46 | 2.14 | 1.75 | 2.96 | 42.79 | 36.02 | 2.87 | 3.34 | 0.8647 | 6.89 | 0.451 | 54.53 | 19.86 | 29.26 | -81.02 | -20.34 | -2.90 | 16.67 |
| AddLife AB | 353.69m | 15.31m | 1.18bn | 1.00k | 79.32 | 8.05 | 32.54 | 3.34 | 1.41 | 1.41 | 32.70 | 13.94 | 1.14 | 5.23 | 5.75 | 3,956,438.00 | 4.98 | -- | 8.51 | -- | 34.69 | -- | 4.37 | -- | 0.4932 | 13.33 | 0.4178 | -- | 40.21 | -- | 8.74 | -- | -- | -- |
| Zealand Pharma Aktieselskabet | 7.22m | -83.71m | 1.29bn | 191.00 | -- | 7.34 | -- | 179.04 | -18.08 | -18.08 | 1.57 | 33.01 | 0.0369 | -- | 3,706.90 | 300,279.30 | -42.82 | -12.24 | -50.73 | -13.75 | -- | -- | -1,160.08 | -84.51 | -- | -- | 0.0769 | -- | 8.84 | -23.11 | -198.32 | -- | 39.22 | -- |
| Karo Pharma AB | 218.12m | 5.30m | 1.30bn | 129.00 | 249.05 | 2.39 | 32.55 | 5.94 | 0.2409 | 0.2409 | 11.37 | 25.12 | 0.2412 | -- | -- | 17,613,940.00 | 0.588 | 3.69 | 0.792 | 4.93 | 51.76 | 53.20 | 2.44 | 15.21 | -- | 1.63 | 0.2848 | 6.46 | 17.71 | 129.20 | -98.65 | -- | 12.32 | -- |
| Cosmo Pharmaceuticals NV | 62.48m | -24.41m | 1.30bn | 245.00 | -- | 3.18 | -- | 20.78 | -1.77 | -1.77 | 4.54 | 28.83 | 0.1032 | 4.97 | 3.93 | -- | -4.05 | 7.99 | -4.16 | 8.40 | 59.91 | 66.30 | -39.19 | 59.49 | 18.86 | -1.38 | 0.2951 | -- | -4.76 | -4.72 | -35.59 | -- | 47.20 | -- |
| Fagron NV | 534.70m | 55.20m | 1.38bn | 2.73k | 25.25 | 5.68 | 16.21 | 2.58 | 0.756 | 0.5559 | 7.32 | 3.36 | 0.7206 | 3.87 | 12.90 | 196,002.60 | 7.50 | 2.77 | 10.16 | 4.97 | 44.89 | 44.28 | 10.41 | 4.50 | 0.8433 | 5.82 | 0.6137 | 14.94 | 13.36 | 3.65 | 28.79 | 5.00 | 1.43 | -39.61 |
| Laboratorios Farmaceuticos ROVI SA | 400.12m | 46.30m | 1.44bn | 1.31k | 30.49 | 4.22 | 23.47 | 3.59 | 0.8396 | 0.8396 | 7.25 | 6.07 | 0.8386 | 1.18 | 5.45 | 305,437.40 | 9.70 | 7.34 | 12.24 | 9.56 | 55.74 | 58.37 | 11.57 | 8.18 | 1.32 | 33.81 | 0.1856 | 19.99 | 25.76 | 9.88 | 119.46 | 10.24 | 10.10 | 0.7117 |
| Bavarian Nordic A/S | 120.97m | 35.90m | 1.53bn | 552.00 | 30.07 | 2.22 | 28.96 | 12.65 | 6.48 | 6.48 | 22.23 | 87.71 | 0.1532 | 3.99 | 7.38 | 2,781,046.00 | 4.55 | -2.82 | 4.94 | -3.61 | 42.26 | 66.79 | 29.68 | -9.59 | 3.44 | 7.84 | 0.4157 | -- | 32.33 | -11.45 | 4.19 | -- | 27.95 | -- |
| Virbac SA | 938.34m | 51.55m | 1.67bn | 4.90k | 32.29 | 3.21 | 15.78 | 1.78 | 6.11 | 6.11 | 111.29 | 61.41 | 0.7229 | 2.44 | 9.34 | 191,615.70 | 4.18 | 1.89 | 5.95 | 2.74 | 47.65 | 45.14 | 5.78 | 2.89 | 0.6558 | 5.21 | 0.4542 | 0.00 | 7.99 | 3.95 | 156.48 | -4.11 | -10.53 | -- |
| BACHEM HOLDING AG | 295.10m | 50.95m | 1.74bn | 1.21k | 67.84 | 8.28 | 23.46 | 5.91 | 3.91 | 3.91 | 22.67 | 32.01 | 0.4972 | 1.07 | 3.79 | 259,697.80 | 8.58 | 8.17 | 11.25 | 10.40 | 29.48 | 31.17 | 17.27 | 16.55 | 1.07 | 32.67 | 0.193 | 81.81 | 11.05 | 11.27 | 16.12 | 13.26 | 15.84 | 8.45 |
| Siegfried Holding AG | 784.04m | 49.99m | 1.79bn | 2.41k | 34.97 | 2.60 | 18.20 | 2.29 | 12.52 | 12.52 | 196.45 | 168.44 | 0.7338 | 2.73 | 3.50 | 346,287.50 | 4.68 | 4.26 | 5.84 | 5.03 | 20.72 | 18.68 | 6.38 | 6.08 | 1.10 | 10.13 | 0.1633 | 22.05 | 4.94 | 21.46 | -5.62 | 6.63 | -5.47 | -- |
Data as of Jul 09 2020. Currency figures normalised to Fagron NV's reporting currency: Euro EUR
32.57%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (World Investors)as of 05 Jun 2020 | 5.34m | 7.40% |
| NN Investment Partners BVas of 10 Apr 2020 | 4.80m | 6.64% |
| Capital International Ltd.as of 05 Jun 2020 | 2.20m | 3.05% |
| Evermore Global Advisors LLCas of 31 Mar 2020 | 2.16m | 2.99% |
| Norges Bank Investment Managementas of 29 May 2020 | 2.15m | 2.99% |
| Carmignac Gestion SAas of 07 Nov 2019 | 2.15m | 2.98% |
| The Vanguard Group, Inc.as of 31 May 2020 | 1.83m | 2.54% |
| KBC Asset Management NVas of 31 Dec 2019 | 1.07m | 1.48% |
| Amundi Asset Management SA (Investment Management)as of 30 Apr 2020 | 903.63k | 1.25% |
| BNP Paribas Asset Management Belgium SAas of 30 Apr 2020 | 890.69k | 1.23% |
More ▼
Data from 31 Dec 2019 - 29 May 2020Source: FactSet Research Systems Inc.
